


MEDICINAL PRODUCTS 2022

Ingevity Corp Rank 28 of 51







RealRate

MEDICINAL PRODUCTS 2022

Ingevity Corp Rank 28 of 51



The relative strengths and weaknesses of Ingevity Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ingevity Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Ingevity Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 46% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	724,900
Assets, Non-Current	161,900
General and Administrative Expense	1,058,000
Goodwill	779,600
Liabilities, Current	383,500
Liabilities, Non-Current	1,411,700
Other Assets	82,900
Other Compr. Net Income	8,400
Other Expenses	113,200
Other Liabilities	0
Other Net Income	-75,900
Other Revenues	1,391,500
Property, Plant and Equipment, Net	719,700
Research and Development	26,300

Output Variable	Value in 1000 USD
Liabilities	1,795,200
Assets	2,469,000
Expenses	1,197,500
Revenues	1,391,500
Stockholders Equity	673,800
Net Income	118,100
Comprehensive Net Income	122,300
Economic Capital Ratio	33%

